Last update Jan. 29, 2017
Very Low Risk
Anti-fibrinolytic drug that is used on the treatment and prophylaxis of hereditary angioedema, menorrhagia and other hemorrhagic disorders.
It is excreted into breast milk in a non-significant amount: the concentration measured in the milk was 1% of plasma concentration (Verstraeten 1985, WHO 2010, Caballero 2012).
Despite of that low observed concentration, an expert consensus did not recommend its use while breastfeeding (Caballero 2012).
No clinical or developmental issues have been observed in the short and long term among 21 infants whose mothers were treated with it. (Gilad 2014).
Scientific societies and some consensus of experts believe it is compatible the use of Tranexamic acid during breastfeeding (WHO 2010, Bouillet 2015).
We do not have alternatives for Tranexamic Acid since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM